Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | LTK | P29376 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | PRKX | P51817 | 1/20 | 0.46 |
| ▸ | NEK2 | P51955 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269719 | 0.80 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL846652 | 0.80 | SCN10A (0.78) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL521629 | 0.79 | MAPT (0.68) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL10220066 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL10248233 | 0.79 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL17191842 | 0.78 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL25913626 | 0.77 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL14336548 | 0.77 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL10284444 | 0.77 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL846648 | 0.77 | KDM4E (0.56) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | ALDH1A1 2404/4885SMN1; SMN2 1240/4885L3MBTL1 151/4885 |
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | DOT1L, CARM1, MCL1 | ALDH1A1 1884/4885SMN1; SMN2 1819/4885L3MBTL1 412/4885 |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | ALDH1A1 1001/4885SMN1; SMN2 3312/4885L3MBTL1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.